{
    "id": 11338,
    "fullName": "RANBP2 - ALK",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "RANBP2-ALK results from the fusion of RANBP2 and ALK, and leads to growth factor-independent cell proliferation in culture (PMID: 21030459). RANBP2-ALK fusions have been identified in inflammatory myofibroblastic tumor, diffuse large B-cell lymphoma, and leukemia (PMID: 12661011, PMID: 24470379, PMID: 24613277).",
            "references": [
                {
                    "id": 5766,
                    "pubMedId": 24470379,
                    "title": "Identification of RANBP2-ALK fusion in ALK positive diffuse large B-cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24470379"
                },
                {
                    "id": 3660,
                    "pubMedId": 21030459,
                    "title": "The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21030459"
                },
                {
                    "id": 5767,
                    "pubMedId": 12661011,
                    "title": "Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12661011"
                },
                {
                    "id": 5764,
                    "pubMedId": 24613277,
                    "title": "RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24613277"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5903,
        "geneSymbol": "RANBP2",
        "terms": [
            "RANBP2",
            "ADANE",
            "ANE1",
            "IIAE3",
            "NUP358",
            "TRP1",
            "TRP2"
        ]
    },
    "variant": "RANBP2 - ALK",
    "createDate": "09/03/2015",
    "updateDate": "04/09/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 238,
                "geneSymbol": "ALK",
                "terms": [
                    "ALK",
                    "CD246",
                    "NBLST3"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 18604,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in significant clinical improvement and partial response lasted for 8 months in a patient with epithelioid inflammatory myofibroblastic sarcoma harboring RANBP2-ALK (PMID: 30675302).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 80372,
                "name": "epithelioid inflammatory myofibroblastic sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16333,
                    "pubMedId": 30675302,
                    "title": "ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30675302"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3169,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with epithelioid inflammatory myofibroblastic sarcoma harboring RANBP2-ALK demonstrated sensitivity to Xalkori (crizotinib), which resulted in tumor shrinkage (PMID: 25028698).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 80372,
                "name": "epithelioid inflammatory myofibroblastic sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3659,
                    "pubMedId": 25028698,
                    "title": "A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25028698"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15384,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RANBP2-ALK demonstrated decreased response to Lorbrena (lorlatinib) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13271,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial (PROFILE 1001), Xalkori (crizotinib) treatment resulted in complete radiographic remission in a patient with inflammatory myofibroblastic tumor harboring RANBP2-ALK fusion (PMID: 20979472; NCT00585195).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11037,
                    "pubMedId": 20979472,
                    "title": "Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20979472"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15383,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RANBP2-ALK demonstrated decreased response to Ensartinib (X-396) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 961,
                "therapyName": "Ensartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8013,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pediatric patient with acute myelomonocytic leukemia harboring RANBP2-ALK demonstrated a complete remission when treated with a combination of Xalkori (crizotinib) and allogeneic hematopoietic cell transplantation (PMID: 27494825).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6535,
                    "pubMedId": 27494825,
                    "title": "Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27494825"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15382,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RANBP2-ALK demonstrated decreased response to Alecensa (alectinib) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13066,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Zykadia (ceritinib) treatment resulted in a partial response that lasted for 11 months in a patient with inflammatory myofibroblastic tumor in the pleural cavity harboring a RANBP2-ALK fusion, whose disease progressed after initial response to ASP3026 (PMID: 27565932).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10946,
                    "pubMedId": 27565932,
                    "title": "Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27565932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15381,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RANBP2-ALK demonstrated decreased response to Xalkori (crizotinib) compared to cells expressing ALK F1174L in culture (PMID: 30002191).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13130,
                    "pubMedId": 30002191,
                    "title": "ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30002191"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13065,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, ASP3026 treatment resulted in rapid initial response in a patient with inflammatory myofibroblastic tumor in the pleural cavity harboring RANBP2-ALK fusion, however, the disease progressed 7 months later (PMID: 27565932).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10946,
                    "pubMedId": 27565932,
                    "title": "Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27565932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12937,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "RANBP2-ALK fusions aid the diagnosis of inflammatory myofibroblastic tumor (NCCN.org).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12760,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, ALK F1174L was identified in a progressing lesion of a patient with inflammatory myofibroblastic tumor harboring RANBP2-ALK, whose disease progressed after initial response to Xalkori (crizotinib) (PMID: 21030459).",
            "molecularProfile": {
                "id": 12109,
                "profileName": "RANBP2 - ALK ALK F1174L"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 50905,
                "name": "inflammatory myofibroblastic tumor",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3660,
                    "pubMedId": 21030459,
                    "title": "The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21030459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3171,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RANBP2-ALK and ALK F1174L were sensitive to TAE684 as demonstrated by inhibition of Alk phosphorylation and repression of cell growth in culture (PMID: 21030459).",
            "molecularProfile": {
                "id": 12109,
                "profileName": "RANBP2 - ALK ALK F1174L"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3660,
                    "pubMedId": 21030459,
                    "title": "The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21030459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3170,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing RANBP2-ALK and ALK F1174L were resistant to Xalkori (crizotinib) in culture (PMID: 21030459).",
            "molecularProfile": {
                "id": 12109,
                "profileName": "RANBP2 - ALK ALK F1174L"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3660,
                    "pubMedId": 21030459,
                    "title": "The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21030459"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18605,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, ALK G1269A was identified as an acquired mutation at disease progression in a patient with epithelioid inflammatory myofibroblastic sarcoma harboring RANBP2-ALK treated with Xalkori (crizotinib) (PMID: 30675302).",
            "molecularProfile": {
                "id": 33477,
                "profileName": "RANBP2 - ALK ALK G1269A"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 80372,
                "name": "epithelioid inflammatory myofibroblastic sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16333,
                    "pubMedId": 30675302,
                    "title": "ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30675302"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18606,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Alunbrig (brigatinib) treatment resulted in rapid clinical improvement and reached a partial response 3 months after treatment in a patient with epithelioid inflammatory myofibroblastic sarcoma harboring RANBP2-ALK and an acquired ALK G1269A (PMID: 30675302).",
            "molecularProfile": {
                "id": 33477,
                "profileName": "RANBP2 - ALK ALK G1269A"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 80372,
                "name": "epithelioid inflammatory myofibroblastic sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16333,
                    "pubMedId": 30675302,
                    "title": "ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30675302"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11387,
            "profileName": "RANBP2 - ALK",
            "profileTreatmentApproaches": [
                {
                    "id": 6485,
                    "name": "ALK Inhibitor",
                    "profileName": "RANBP2 - ALK"
                }
            ]
        },
        {
            "id": 12109,
            "profileName": "RANBP2 - ALK ALK F1174L",
            "profileTreatmentApproaches": [
                {
                    "id": 16868,
                    "name": "TAE684",
                    "profileName": "RANBP2 - ALK ALK F1174L"
                }
            ]
        },
        {
            "id": 33477,
            "profileName": "RANBP2 - ALK ALK G1269A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}